Details of the Drug Combination

General Information of Drug Combination (ID: DC54IXR)

Drug Combination Name
Naloxone Sulfasalazine
Indication
Disease Entry Status REF
Intestinal Obstruction Phase 1 [1]
Component Drugs Naloxone   DM3FXMA Sulfasalazine   DMICA9H
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Naloxone
Disease Entry ICD 11 Status REF
Narcotic depression 6A7Z Approved [2]
Pain MG30-MG3Z Approved [3]
Pruritus EC90 Phase 3 [4]
Respiratory depression MD11.5 Phase 3 [5]
Opioid dependence 6C43.2Z Phase 1 [5]
Naloxone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Antagonist [10]
------------------------------------------------------------------------------------
Naloxone Interacts with 10 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Renin (REN) OT52GZR2 RENI_HUMAN Increases Activity [11]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Decreases Expression [12]
Vasopressin-neurophysin 2-copeptin (AVP) OTAVZ76K NEU2_HUMAN Decreases Secretion [13]
Pro-opiomelanocortin (POMC) OTV41F7T COLI_HUMAN Increases Expression [14]
Lutropin subunit beta (LHB) OT5GBOVJ LSHB_HUMAN Increases Expression [15]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Affects Expression [16]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Response To Substance [17]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [18]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Affects Binding [19]
Interleukin-2 (IL2) OTGI4NSA IL2_HUMAN Decreases Response To Substance [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DOT(s)
Indication(s) of Sulfasalazine
Disease Entry ICD 11 Status REF
Irritable bowel syndrome DD91.0 Approved [6]
Rheumatoid arthritis FA20 Approved [7]
Ulcerative colitis DD71 Approved [8]
Sulfasalazine Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ATP-binding cassette transporter G2 (ABCG2) TTIMJ02 ABCG2_HUMAN Inhibitor [23]
Nuclear factor NF-kappa-B (NFKB) TTSXVID NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN Activator [24]
------------------------------------------------------------------------------------
Sulfasalazine Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [25]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [26]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [27]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [28]
------------------------------------------------------------------------------------
Sulfasalazine Interacts with 12 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [29]
Azoreductase (azoR) DE5CAX1 A0A074IU04_STRSL Metabolism [30]
Azoreductase (azoR) DEGTKHL T0VG26_9ENTE Metabolism [31]
Azoreductase (azoR) DE3UF6Z A0A0P0ETC6_BACT4 Metabolism [31]
Azoreductase (azoR) DE6GHJ5 A0A0P0ETC6_BACT4 Metabolism [31]
Azoreductase (azoR) DEEISQ2 AZOR_ENTFA Metabolism [30]
Azoreductase (azoR) DEI2PC5 AZOR_CLOP1 Metabolism [30]
Azoreductase (azoR) DETEMAH A0A349MYB4_9LACO Metabolism [31]
Azoreductase (azoR) DEM1BHT A0A132Z973_ENTFC Metabolism [30]
Azoreductase (azoR) DEIKZOU A0A0P0ETC6_BACT4 Metabolism [32]
Azoreductase (azoR) DENLBG3 A0A0P0ETC6_BACT4 Metabolism [30]
Azoreductase (azoR) DEIHK8V A0A349MYB4_9LACO Metabolism [30]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DME(s)
Sulfasalazine Interacts with 33 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Decreases Methylation [33]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Decreases Expression [21]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Increases Activity [34]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) OTQ4W7MT TR11B_HUMAN Increases Secretion [35]
Tumor necrosis factor ligand superfamily member 11 (TNFSF11) OTJEPKEQ TNF11_HUMAN Decreases Expression [35]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) OT9RDS3H IKKB_HUMAN Decreases Expression [36]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [37]
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial (CYP27B1) OTTK98BH CP27B_HUMAN Decreases Expression [38]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Affects Localization [39]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Response To Substance [40]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [41]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases Expression [42]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [22]
Insulin receptor (INSR) OTTY341H INSR_HUMAN Increases Expression [36]
Tropomyosin alpha-3 chain (TPM3) OT5RU5G6 TPM3_HUMAN Decreases Expression [43]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Affects Secretion [44]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [41]
E-selectin (SELE) OT33RZWY LYAM2_HUMAN Increases Expression [45]
Thromboxane-A synthase (TBXAS1) OTAXZJJ4 THAS_HUMAN Decreases Activity [46]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Decreases Expression [47]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [39]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Cleavage [48]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Activity [36]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Affects Localization [39]
MHC class I polypeptide-related sequence A (MICA) OTPEIEAR MICA_HUMAN Decreases Expression [49]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [50]
Proton-coupled folate transporter (SLC46A1) OT049V7Y PCFT_HUMAN Decreases Activity [51]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [37]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Activity [52]
Arylamine N-acetyltransferase 2 (NAT2) OTBPDQOY ARY2_HUMAN Increases Acetylation [53]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases ADR [54]
Myeloperoxidase (MPO) OTOOXLIN PERM_HUMAN Increases ADR [54]
Methylenetetrahydrofolate reductase (MTHFR) OTUBJSR7 MTHR_HUMAN Increases Response To Substance [55]
------------------------------------------------------------------------------------
⏷ Show the Full List of 33 DOT(s)

References

1 ClinicalTrials.gov (NCT01596764) Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1668).
3 Naloxone FDA Label
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4840).
8 Sulfasalazine FDA Label
9 Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury. Arch Toxicol. 2018 Jan;92(1):383-399. doi: 10.1007/s00204-017-2036-4. Epub 2017 Jul 31.
10 OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7.
11 beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
12 Opioid peptides attenuate blood pressure increase in acute respiratory failure. Peptides. 2001 Apr;22(4):631-7. doi: 10.1016/s0196-9781(01)00373-4.
13 Blood pressure and vasopressin in progressive autonomic failure. Response to postural stimulation, L-dopa and naloxone. Brain. 1983 Jun;106 (Pt 2):503-11. doi: 10.1093/brain/106.2.503.
14 Endogenous opioids modulate the cardiovascular response to mental stress. Psychoneuroendocrinology. 1990;15(3):185-92. doi: 10.1016/0306-4530(90)90029-9.
15 Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states. J Clin Endocrinol Metab. 1987 Mar;64(3):508-12. doi: 10.1210/jcem-64-3-508.
16 Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
17 Central opioid inhibition of neuroendocrine stress responses in pregnancy in the rat is induced by the neurosteroid allopregnanolone. J Neurosci. 2009 May 20;29(20):6449-60. doi: 10.1523/JNEUROSCI.0708-09.2009.
18 Chronic oxycodone induces integrated stress response in rat brain. BMC Neurosci. 2015 Sep 16;16:58. doi: 10.1186/s12868-015-0197-8.
19 Human carboxylesterase 1: from drug metabolism to drug discovery. Biochem Soc Trans. 2003 Jun;31(Pt 3):620-4. doi: 10.1042/bst0310620.
20 Interleukin-2-induced antinociception in morphine-insensitive rats. Acta Pharmacol Sin. 2002 Nov;23(11):981-4.
21 Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells. Mol Pharmacol. 2004 Oct;66(4):1054-60.
22 [The effects of anti-inflammatory on activation of nuclear factor-kappaB and expression of cell adhesion molecules in patients with ulcerative colitis]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2004 Oct;21(5):732-6.
23 The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996 Mar 1;156(5):1937-41.
24 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
25 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
26 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
27 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
28 Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
29 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
30 The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
31 The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555-62.
32 Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467.
33 Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia. 2009 Dec;11(12):1359-70. doi: 10.1593/neo.91314.
34 Identification of chemical compounds that induce HIF-1alpha activity. Toxicol Sci. 2009 Nov;112(1):153-63.
35 Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum. 2004 Dec;50(12):3831-43. doi: 10.1002/art.20637.
36 Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology. 2005 Mar;146(3):1491-7. doi: 10.1210/en.2004-0809. Epub 2004 Nov 24.
37 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
38 Down-regulation by nuclear factor kappaB of human 25-hydroxyvitamin D3 1alpha-hydroxylase promoter. Mol Endocrinol. 2004 Oct;18(10):2440-50. doi: 10.1210/me.2002-0441. Epub 2004 Jul 8.
39 Molecular mechanisms of sulfasalazine-induced T-cell apoptosis. Br J Pharmacol. 2002 Nov;137(5):608-20. doi: 10.1038/sj.bjp.0704870.
40 Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
41 [Activation of nuclear factor-kappaB and its relationship with cytokine gene expression in colonic mucosa of ulcerative colitis patients]. Zhonghua Nei Ke Za Zhi. 2002 Apr;41(4):252-5.
42 Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis. Ann Rheum Dis. 2007 Oct;66(10):1289-95. doi: 10.1136/ard.2006.060509. Epub 2007 Jan 31.
43 Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia. Mol Pharmacol. 2009 Jul;76(1):183-91. doi: 10.1124/mol.109.056028. Epub 2009 Apr 15.
44 The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production. Exp Mol Pathol. 2002 Oct;73(2):84-92. doi: 10.1006/exmp.2002.2460.
45 Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood. 2001 Apr 1;97(7):1937-41. doi: 10.1182/blood.v97.7.1937.
46 Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products. Eur J Pharmacol. 1989 Oct 10;169(2-3):225-34. doi: 10.1016/0014-2999(89)90019-8.
47 Nuclear factor-kappa B activation in human testicular apoptosis. Am J Pathol. 2002 Jan;160(1):205-18. doi: 10.1016/s0002-9440(10)64364-7.
48 Sulfasalazine induces apoptosis of HBx-expressing cells in an NF-kappaB-independent manner. Virus Genes. 2010 Feb;40(1):37-43. doi: 10.1007/s11262-009-0416-4. Epub 2009 Oct 27.
49 NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol. 2004 Nov 1;173(9):5583-90. doi: 10.4049/jimmunol.173.9.5583.
50 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
51 Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther. 2007 Aug;322(2):469-76. doi: 10.1124/jpet.107.122606. Epub 2007 May 2.
52 Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. J Pharmacol Exp Ther. 2010 Mar;332(3):949-58. doi: 10.1124/jpet.109.162248. Epub 2009 Dec 9.
53 Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol. 2002 Dec;29(12):2492-9.
54 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
55 The effect of 677C>T and 1298A>C MTHFR polymorphisms on sulfasalazine treatment outcome in rheumatoid arthritis. Braz J Med Biol Res. 2009 Jul;42(7):660-4. doi: 10.1590/s0100-879x2009000700011.